Biotech Values

[DewDiligence]

…don't you feel that either a dismissal or worse yet an outright loss will weaken the market perception of MNTA—as an astute group of businessmen, something the street needs to believe—and by association the science and the product itself?

No, not at all. If MNTA can show prospective partners for its FoB, M118, and M402 programs that Teva has ceased boasting about its purported prowess in characterizing complex-mixture drugs, the lawsuit will have accomplished its objective.

Not to mention the PPS.

The share price will take care of itself in due course as cash piles up on the balance sheet and business deals are announced for the various programs in MNTA’s pipeline.